Cabaletta Bio (CABA) Competitors $1.50 -0.01 (-0.33%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CABA vs. XNCR, ANAB, PVLA, ARVN, SAGE, ORKA, SVRA, GOSS, RAPP, and SEPNShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Xencor (XNCR), AnaptysBio (ANAB), Palvella Therapeutics (PVLA), Arvinas (ARVN), Sage Therapeutics (SAGE), Oruka Therapeutics (ORKA), Savara (SVRA), Gossamer Bio (GOSS), Rapport Therapeutics (RAPP), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Its Competitors Xencor AnaptysBio Palvella Therapeutics Arvinas Sage Therapeutics Oruka Therapeutics Savara Gossamer Bio Rapport Therapeutics Septerna Cabaletta Bio (NASDAQ:CABA) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership. Which has more risk & volatility, CABA or XNCR? Cabaletta Bio has a beta of 2.74, suggesting that its share price is 174% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Is CABA or XNCR more profitable? Cabaletta Bio has a net margin of 0.00% compared to Xencor's net margin of -121.52%. Xencor's return on equity of -25.75% beat Cabaletta Bio's return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -92.11% -74.08% Xencor -121.52%-25.75%-18.19% Does the media refer more to CABA or XNCR? In the previous week, Xencor had 6 more articles in the media than Cabaletta Bio. MarketBeat recorded 8 mentions for Xencor and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.94 beat Xencor's score of 0.72 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, CABA or XNCR? Cabaletta Bio has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$115.86M-$2.71-0.55Xencor$146.93M3.89-$232.62M-$2.40-3.34 Do analysts recommend CABA or XNCR? Cabaletta Bio presently has a consensus price target of $14.43, indicating a potential upside of 865.12%. Xencor has a consensus price target of $23.71, indicating a potential upside of 196.24%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Cabaletta Bio is more favorable than Xencor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Xencor 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryCabaletta Bio beats Xencor on 8 of the 14 factors compared between the two stocks. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$135.82M$3.06B$5.75B$9.85BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-0.5521.1531.3126.63Price / SalesN/A383.94459.79120.56Price / CashN/A44.4437.7659.36Price / Book0.778.0810.026.70Net Income-$115.86M-$54.08M$3.27B$265.68M7 Day Performance-6.56%2.44%3.26%3.46%1 Month Performance-11.54%3.56%4.45%1.11%1 Year Performance-73.95%18.78%44.34%24.00% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio2.526 of 5 stars$1.50-0.3%$14.43+865.1%-74.0%$135.82MN/A-0.5550XNCRXencor3.6884 of 5 stars$8.01-4.8%$23.71+196.1%-53.2%$571.30M$146.93M-3.34280Positive NewsANABAnaptysBio1.9237 of 5 stars$20.10-0.6%$46.13+129.5%-44.6%$562.74M$123.16M-4.49100Positive NewsPVLAPalvella Therapeutics2.7532 of 5 stars$50.13-6.2%$58.50+16.7%N/A$554.44M$42.81M-4.14N/AARVNArvinas3.917 of 5 stars$7.48+2.2%$19.76+164.2%-68.6%$549.17M$372.80M-7.41420Positive NewsSAGESage Therapeutics3.6895 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690News CoverageORKAOruka Therapeutics2.5093 of 5 stars$14.51-6.0%$40.38+178.3%N/A$543.41MN/A-5.16N/ASVRASavara2.4551 of 5 stars$3.14-0.6%$6.17+96.4%-23.8%$542.72MN/A-6.2820GOSSGossamer Bio3.8059 of 5 stars$2.36+0.9%$8.50+260.2%+169.2%$536.62M$114.70M-3.81180RAPPRapport Therapeutics1.7907 of 5 stars$14.63-0.9%$29.50+101.6%-26.6%$534.00MN/A-5.85N/APositive NewsGap UpSEPNSepterna1.6835 of 5 stars$11.96-0.3%$26.75+123.7%N/A$533.18M$1.08M-1.19N/A Related Companies and Tools Related Companies XNCR Competitors ANAB Competitors PVLA Competitors ARVN Competitors SAGE Competitors ORKA Competitors SVRA Competitors GOSS Competitors RAPP Competitors SEPN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CABA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access